Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.
about
Onto better TRAILs for cancer treatmentCaloric restriction: is mammalian life extension linked to p53?Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)Hormesis, cell death and aging.Cell death in disease: from 2010 onwardsTRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.The design and characterization of receptor-selective APRIL variantsDelivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effectsNovel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation.N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress.Immunomodulation using agonists and antagonists: potential clinical applications.Role of the promyelocytic leukaemia protein in cell death regulation.Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity.CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma.A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome.Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells.Highly sensitive antibody-free μLC-MS/MS quantification of rhTRAIL in serum.Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells
P2860
Q26768160-47FB0BA7-78DB-4E2E-A694-40347B351A44Q26829232-FE068ED0-1C5A-49ED-A819-2F30D638F8EEQ26859211-8B064AC3-9C4D-4583-87CF-26B8F0D48436Q34217654-0B3C4506-91D5-48BB-8572-F34BA943D310Q35269870-C80640A6-AC51-46D8-B06B-DC8861153AA9Q35681794-5BA9CD7B-4FC0-4489-B102-7E3FBDB6AF47Q35853714-5C9AA927-A335-4E8C-BFF1-E1D189C23BC8Q35863285-E4C0E162-4C84-40F7-A32F-E381A8F1E05AQ36215003-B62B7839-3307-4094-A9E5-CDF03CCBA45BQ36347872-8D87C6C2-F822-425A-88FA-C9BA85FFECC7Q37073589-2587150D-2E8E-4EB7-9857-0286799DC9C4Q37520449-9CF7CEFD-3396-4ADF-BB1D-1026CA4ABA66Q37599015-AA8C69B0-A2AC-46E7-A287-FFA56327B8A8Q37691437-2E4A8F91-8A56-498F-BAFC-182FAD711828Q37706093-C25362B0-BC06-443A-81AD-7EDED535B526Q37965728-F3A7B497-C74B-4C26-A9D8-53C3540AF809Q37975087-F67593ED-38ED-4979-B329-5E69457E0B90Q38866710-BF8D00EC-EABD-4D21-9B93-DA56C634FE07Q39028796-204C95F7-9BDA-42F2-9D0A-28458A53D706Q39054114-9D0129C8-5D22-4703-8ADC-61015DEDBB4FQ39063100-F463F69F-D06F-4D4A-93DA-968981F3D659Q42037754-106A840A-59BB-4F58-9883-B1ECA4ECD0C6Q42632659-73E29A50-E8CD-4A23-895E-77C4AE8D944AQ42968961-4E78B2D2-486F-4954-BE64-8B0A6546ADA9Q47844332-AD55C48D-B70D-45DC-B7CC-7F347210D943Q51045188-B4D9D42D-FAF7-465E-9C86-4F6D0D627BEFQ51373757-D0F33500-FA65-430E-8AD0-9CA15379026BQ52715823-1507AB60-DAF0-4308-8E57-13D4E1339557Q59134014-BE9C5FD6-D713-43BB-BA27-1250B748F442
P2860
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@ast
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@en
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@nl
type
label
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@ast
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@en
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@nl
prefLabel
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@ast
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@en
Rapid and efficient cancer cel ...... omotrimerizing TRAIL variants.
@nl
P2093
P2860
P50
P356
P1476
Rapid and efficient cancer cel ...... homotrimerizing TRAIL variants
@en
P2093
F Stricher
K Sjollema
R Setroikromo
P2860
P356
10.1038/CDDIS.2010.61
P577
2010-10-21T00:00:00Z